-
Tytuł:
-
Tissue Expression of Androgen Receptor Splice Variant 7 at Radical Prostatectomy Predicts Risk of Progression in Untreated Nonmetastatic Prostate Cancer.
-
Autorzy:
-
Sciarra A; Department of Urology, Sapienza Rome University, Policlinico Umberto I, Rome, Italy.
Maggi M; Department of Urology, Sapienza Rome University, Policlinico Umberto I, Rome, Italy, .
Salciccia S; Department of Urology, Sapienza Rome University, Policlinico Umberto I, Rome, Italy.
Nicolai A; Department of Experimental Medicine, Sapienza Rome University, Policlinico Umberto I, Rome, Italy.
Tortorella E; Department of Molecular Medicine, Sapienza Rome University, Policlinico Umberto I, Rome, Italy.
Giantulli S; Department of Molecular Medicine, Sapienza Rome University, Policlinico Umberto I, Rome, Italy.
Magliocca FM; Department of Radiological, Oncological and Anatomopathological Sciences, Sapienza Rome University, Policlinico Umberto I, Rome, Italy.
Silvestri I; Department of Molecular Medicine, Sapienza Rome University, Policlinico Umberto I, Rome, Italy.
Taglieri L; Department of Experimental Medicine, Sapienza Rome University, Policlinico Umberto I, Rome, Italy.
Cattarino S; Department of Urology, Sapienza Rome University, Policlinico Umberto I, Rome, Italy.
Scarpa S; Department of Experimental Medicine, Sapienza Rome University, Policlinico Umberto I, Rome, Italy.
-
Źródło:
-
Oncology [Oncology] 2021; Vol. 99 (4), pp. 251-255. Date of Electronic Publication: 2021 Jan 18.
-
Typ publikacji:
-
Wiadomości
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: Basel, New York, Karger.
-
MeSH Terms:
-
Disease Progression*
Prostatectomy/*methods
Prostatic Neoplasms, Castration-Resistant/*metabolism
Prostatic Neoplasms, Castration-Resistant/*surgery
Receptors, Androgen/*metabolism
Aged ; Biomarkers, Tumor/metabolism ; Humans ; Immunohistochemistry ; Male ; Middle Aged ; Prognosis ; Progression-Free Survival ; Prostatic Neoplasms, Castration-Resistant/mortality ; Prostatic Neoplasms, Castration-Resistant/pathology ; Protein Isoforms/metabolism ; Receptors, Androgen/genetics ; Retrospective Studies ; Risk
-
Contributed Indexing:
-
Keywords: Androgen receptor; Prostate cancer; Radical prostatectomy
-
Substance Nomenclature:
-
0 (AR protein, human)
0 (Biomarkers, Tumor)
0 (Protein Isoforms)
0 (Receptors, Androgen)
-
Entry Date(s):
-
Date Created: 20210118 Date Completed: 20210414 Latest Revision: 20210414
-
Update Code:
-
20240105
-
DOI:
-
10.1159/000512445
-
PMID:
-
33461196
-
Background: Androgen receptor splice variant V7 (AR-V7) was recently detected in circulating tumor cells of castration-resistant prostate cancer (PC) patients and its expression correlated with resistance to new-generation androgen signaling inhibitors.
Objectives: We retrospectively analyzed whether AR-V7 expression was detectable on radical prostatectomy (RP) specimens of untreated nonmetastatic PC cases, and whether it could be associated with progression after surgery.
Method: The expression of AR-V7 and AR-FL (full length) was separately evaluated by immunohistochemistry using a streptavidin-biotin-peroxidase system with 2 anti-AR-V7 and anti-AR-FL rabbit monoclonal antibodies.
Results: 56 PC cases, classified by their clinical risk, were analyzed. Positive expression was found in 24/32 cases in the high-risk group, 4/13 in the intermediate-risk group, and only 2/11 in the low-risk group. We found a significant correlation between AR-V7 positivity and both risk classification (p < 0.001) and progression after surgery (p < 0.001).
Conclusions: In our population of untreated nonmetastatic PC, AR-V7 is detectable by immunohistochemistry in more than 50% of cases. At this early stage, AR-V7 positivity is associated with risk classification and it can predict progression after surgery.
(© 2021 S. Karger AG, Basel.)
